Creative Biolabs has announced an expansion of its advanced single-cell multi-omics and RNA sequencing solutions, a move that carries significant implications for biomedical research across oncology, immunology, and neuroscience. The upgraded suite is designed to meet the escalating demand for high-resolution cellular profiling, providing end-to-end services that range from single-cell transcriptome profiling to integrated multimodal and multi-omics workflows.
As life science research transitions from bulk tissue profiling to single-cell resolution, dissecting cellular heterogeneity has become essential for identifying rare cell subpopulations, characterizing complex tumor microenvironments, and tracing cell lineage trajectories. To support these critical pipelines, Creative Biolabs delivers robust, high-throughput single-cell RNA sequencing services that offer high sensitivity and coverage across thousands of individual cells, delivering high-resolution transcriptomic insights from diverse fresh biological specimens.
The expanded platform also addresses a long-standing laboratory challenge: processing complex, fibrous, or biobanked archival samples. For tissues where single-cell dissociation is prone to cell damage, dissociation-induced stress responses, or selective loss of fragile cell types—such as human brain, myocardium, or flash-frozen clinical biopsies—Creative Biolabs provides an optimized single-cell nuclei RNA sequencing service. By isolating intact nuclei, this approach bypasses harsh enzymatic dissociation, minimizes dissociation-related artifacts, and retains informative nuclear RNA profiles, dramatically expanding the scope of clinical translational research.
Recognizing that cellular identity is orchestrated across multiple regulatory layers, Creative Biolabs goes beyond single-dimensional analysis by advancing its high-throughput single-cell multi-omics service. This integrated platform allows the simultaneous interrogation of genomic variations, epigenomic landscapes such as chromatin accessibility, cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By directly linking epigenetic regulation and genomic alterations to gene expression readouts, the service enables researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with unprecedented biological clarity.
“Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery,” said a senior scientist at Creative Biolabs. “Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support.”
The importance of this expansion lies in its potential to democratize access to advanced single-cell technologies. Many research teams, particularly those in translational medicine, face hurdles in processing challenging samples or integrating multi-omics data. By offering specialized single-nucleus RNA sequencing and multi-omics workflows, Creative Biolabs removes technical barriers that have historically limited the study of fragile or archived tissues. This can accelerate discoveries in neurodegenerative diseases, cardiac disorders, and cancer, where cellular heterogeneity and rare cell populations play critical roles. Furthermore, the ability to link epigenomic and proteomic data to transcriptomes within the same cell provides a more complete picture of regulatory mechanisms, potentially leading to more precise therapeutic interventions.
Supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, Creative Biolabs continues to partner with academic and biopharmaceutical research teams worldwide to unravel the complexities of human disease. For more information about Creative Biolabs and its full suite of single-cell analytical solutions, please visit https://singlecell.creative-biolabs.com/.
